ArticlePloS one2015
Eye Movement Deficits Are Consistent with a Staging Model of pTDP-43 Pathology in Amyotrophic Lateral Sclerosis.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Exploring amyotrophic lateral sclerosis through the visual system: A systematic review.European journal of neurology · 2024Pooled it
- Oculomotor atypicalities in motor neurone disease: a systematic review.Frontiers in neuroscience · 2024Pooled it
- Ethical challenges in treatment-goal transitions in invasively ventilated ALS: a case-based topical review.Neurological research and practice · 2026Review
- Atypical features including acquired oculomotor apraxia inJournal of neuromuscular diseases · 2026Article
- Eye tracking as a digital biomarker in neurodegenerative diseases.Journal of neurology · 2026Review
- An EEG & eye-tracking dataset of ALS patients & healthy people during eye-tracking-based spelling system usage.Scientific data · 2024Article
- Impairment of oculomotor functions in patients with early to advanced amyotrophic lateral sclerosis.Journal of neurology · 2024Article
- Biomarkers in amyotrophic lateral sclerosis: current status and future prospects.Nature reviews. Neurology · 2023Review
- Altered Gaze Control During Emotional Face Exploration in Patients With Amyotrophic Lateral Sclerosis.Neurology · 2023Article
- Multimodal in vivo staging in amyotrophic lateral sclerosis using artificial intelligence.Annals of clinical and translational neurology · 2022Article
- Eye Movement Abnormalities in Amyotrophic Lateral Sclerosis.Brain sciences · 2022Article
- Motor-Independent Cognitive Testing in Motor Degenerative Diseases.Journal of clinical medicine · 2022Article
- Eye Movement Abnormalities in Amyotrophic Lateral Sclerosis in a Tunisian Cohort.Neuro-ophthalmology (Aeolus Press) · 2022Article
- Association of Clinically Evident Eye Movement Abnormalities With Motor and Cognitive Features in Patients With Motor Neuron Disorders.Neurology · 2021Article
- Diagnostic value of video-oculography in progressive supranuclear palsy: a controlled study in 100 patients.Journal of neurology · 2021Article
- Eye movement alterations in presymptomatic C9orf72 expansion gene carriers.Journal of neurology · 2021Article
- A dataset of EEG and EOG from an auditory EOG-based communication system for patients in locked-in state.Scientific data · 2021Article
- Ocular Involvement Occurs Frequently at All Stages of Amyotrophic Lateral Sclerosis: Preliminary Experience in a Large Italian Cohort.Journal of clinical neurology (Seoul, Korea) · 2021Article
- Saccadic intrusions in amyotrophic lateral sclerosis (ALS).Journal of eye movement research · 2019Article
- Cursive Eye-Writing With Smooth-Pursuit Eye-Movement Is Possible in Subjects With Amyotrophic Lateral Sclerosis.Frontiers in neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe neuropathological process underlying amyotrophic lateral sclerosis (ALS) can be traced as a four-stage progression scheme of sequential corticofugal axonal spread. The examination of eye movement control gains deep insights into brain network pathology and provides the opportunity to detect both disturbance of the brainstem oculomotor circuitry as well as executive deficits of oculomotor function associated with higher brain networks.
objectiveTo study systematically oculomotor characteristics in ALS and its underlying network pathology in order to determine whether eye movement deterioration can be categorized within a staging system of oculomotor decline that corresponds to the neuropathological model.
methodsSixty-eight ALS patients and 31 controls underwent video-oculographic, clinical and neuropsychological assessments.
resultsOculomotor examinations revealed increased anti- and delayed saccades' errors, gaze-palsy and a cerebellary type of smooth pursuit disturbance. The oculomotor disturbances occurred in a sequential manner: Stage 1, only executive control of eye movements was affected. Stage 2 indicates disturbed executive control plus 'genuine' oculomotor dysfunctions such as gaze-paly. We found high correlations (p<0.001) between the oculomotor stages and both, the clinical presentation as assessed by the ALS Functional Rating Scale (ALSFRS) score, and cognitive scores from the Edinburgh Cognitive and Behavioral ALS Screen (ECAS).
conclusionsDysfunction of eye movement control in ALS can be characterized by a two-staged sequential pattern comprising executive deficits in Stage 1 and additional impaired infratentorial oculomotor control pathways in Stage 2. This pattern parallels the neuropathological staging of ALS and may serve as a technical marker of the neuropathological spreading.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.